MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of common stock,...
$6,045K
Proceeds from the
issuance of pre-funded...
$3,309K
Proceeds from the
issuance of common stock...
$1,284K
Proceeds from the
issuance of common stock...
$47K
Cash provided by
financing activities
$4,259K
Canceled cashflow
$6,426K
Net increase in cash
and cash...
-$22,561K
Canceled cashflow
$4,259K
Stock-based compensation
expense
$3,118K
Noncash lease expense
$1,103K
Prepaid expenses and
other assets
-$615K
Depreciation expense
$266K
Noncash interest and
other expense, net
$85K
Repayment of loan
$6,426K
Cash used in
operating activities
-$26,820K
Canceled cashflow
$5,187K
Net loss
-$26,262K
Accrued expenses and
other liabilities
-$3,404K
Accounts payable
-$1,412K
Operating lease
liabilities
-$870K
Interest payable
-$59K
Back
Back
Cash Flow
source: myfinsight.com
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST)